Lantheus HoldingsSTU:0L8 +1.37%87 FCF Margin % is 32.31% as of Mar. 2026, which is 110% above its 10-year median of 15.39. GuruFocus rates STU:0L8 with a GF Score™ of 87/100 and a GF Value™ of €79.89 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, Lantheus Holdings ranks better than 93.3% on this metric.
The historical rank and industry rank for Lantheus Holdings's FCF Margin % or its related term are showing as below:
STU:0L8'
s FCF Margin % Range Over the Past 10 Years
Min: 1.16 Med: 15.39 Max: 30.32
Current: 24.05
During the past 13 years, the highest FCF Margin % of Lantheus Holdings was 30.32%. The lowest was 1.16%. And the median was 15.39%.
STU:0L8's FCF Margin % is ranked better than 93.3% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs STU:0L8: 24.05
Lantheus Holdings FCF Margin % Related Terms
Lantheus Holdings FCF Margin % Historical Data
* Premium members only.
The historical data trend for Lantheus Holdings's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0L8 vs LQDA, HIMS, AMRX: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings (STU:0L8) has a FCF Margin % of 32.31% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Lantheus Holdings and its competitors. This is 110% above median its historical median of 15.39. Over the past decade, Lantheus Holdings' FCF Margin % has ranged from 1.16 to 30.32. According to the industry distribution chart, Lantheus Holdings ranks #64 out of 955 companies in the Drug Manufacturers industry, placing it in the top 6.7%.
Is Lantheus Holdings' FCF Margin % too high?
Lantheus Holdings' current FCF Margin % of 32.31% is 110% above median its 10-year median of 15.39. Over the past 10 years, this metric has ranged from a low of 1.16 to a high of 30.32. The Drug Manufacturers industry median FCF Margin % is 2.51. Lantheus Holdings' value of 32.31% is 1187.3% above this industry median. Based on the distribution chart, Lantheus Holdings ranks #64 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Lantheus Holdings has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' FCF Margin % compare to LQDA and HIMS?
According to the Drug Manufacturers industry distribution chart, Lantheus Holdings ranks #64 out of 955 companies for FCF Margin %. This places Lantheus Holdings in the top 7% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.51. Lantheus Holdings' value of 32.31% is 1187.3% above this benchmark. Historically, Lantheus Holdings' own FCF Margin % has ranged from 1.16 to 30.32 over the past decade. While the company's 10-year median is 15.39 vs. the industry median of 2.51, Lantheus Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantheus Holdings's current FCF Margin % of 32.31% is 1187.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Lantheus Holdings and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantheus Holdings's current FCF Margin % is 32.31%, which is 110% above median its own 10-year median of 15.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (STU:0L8) is currently considered Modestly Overvalued. The stock's GF Value™ is €79.89, compared to a current price of €96.50 — trading 20.8% above its estimated fair value. The current FCF Margin % is 32.31%, which is 110% above median its 10-year median of 15.39 and 1187.3% above the Drug Manufacturers industry median of 2.51. Lantheus Holdings' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Lantheus Holdings (STU:0L8), the current FCF Margin % is 32.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (STU:0L8) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of €96.50 is trading 20.8% above its estimated GF Value™ of €79.89.
GuruFocus considers Lantheus Holdings to be Modestly Overvalued.
Key valuation signals for STU:0L8:
FCF Margin %: 32.31% (110% above median its 10-year median of 15.39)
GF Value™: €79.89 vs. price of €96.50 (20.8% above fair value)
Industry Position: 1187.3% above the Drug Manufacturers median (#64 of 955)
No single metric tells the full story. See the STU:0L8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
87GF Score
Get the complete analysis for STU:0L8
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0L8 has been successfully added to your 
